From Bench to Bedside: Immunotherapy for Prostate Cancer

The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, i...

Full description

Saved in:
Bibliographic Details
Main Authors: Tse, Brian Wan-Chi, Jovanovic, Lidija, Nelson, Colleen Coyne, de Souza, Paul, Power, Carl Andrew, Russell, Pamela Joan
Format: Artigo
Language:Inglês
Published: Hindawi Publishing Corporation 2014
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4168152/
https://ncbi.nlm.nih.gov/pubmed/25276838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/981434
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items